| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
EVP, Chief Commercial Officer
1 company
Terrence O Moore last filed a Form 4 in March 2017, as EVP, Chief Commercial Officer at ACAD. Terrence O Moore's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
At the last filing, the largest reported position was 1,671 shares of ACAD. The ACAD filings lean toward selling, a net 165,396 shares.
Terrence O Moore has 5 Form 4 filings on record from March 2015 to March 2017, all as EVP, Chief Commercial Officer at Acadia Pharmaceuticals (ACAD), 2015–2017.
The 13 reported transactions were 6 option exercises, 4 open-market sales and 3 option or other derivative awards.
Counted by filing, the open-market trades come to no purchases and 2 sales worth about $6.6M.
The largest open-market sale was 157,540 shares of ACAD at an average $39.77 on February 16, 2017, about $6.3M.
Shares as reported in the last Form 4 for each company; the most recent is from March 2017. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.